Victor Kenyon

Victor Kenyon

Auto-generated profile, based on publicly available information

Victor Kenyon

Atomwise Inc., San Francisco, CA 94103, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JDJoshua D. Deschamps
Joshua D. Deschamps
VKVictor A. Kenyon
Victor A. Kenyon
THTheodore R. Holman
Theodore R. Holman

1 July 2012 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
JWJessica R. Weaver
Jessica R. Weaver
THTheodore R. Holman
Theodore R. Holman
YIYumi Imai
Yumi Imai
AJAjit Jadhav
Ajit Jadhav
VKVictor Kenyon
Victor Kenyon
DTDavid A. Taylor-Fishwick
David A. Taylor-Fishwick

31 March 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
GRGanesha Rai
Ganesha Rai
NJNetra Joshi
Netra Joshi
JJJoo Eun Jung
Joo Eun Jung
YLYu Liu
Yu Liu
LSLena Schultz
Lena Schultz
THTheodore R. Holman
Theodore R. Holman
A key challenge facing drug discovery today is variability of the drug target between species, such as with 12/15-lipoxygenase (12/15-LOX), which contributes to ischemic brain injury, but its human and rodent isozymes have different inhibitor specificities. In the current work, we have utilized a quantitative high-throughput (qHTS) screen to identify compound 1 (ML351), a novel chemotype for 12/15-LOX inhibition that has nanomolar potency (IC50 = 200 nM) against human 12/15-LOX and is protective against oxidative glutamate toxicity in mouse neuronal HT22 cells. In addition, it exhibited greater than 250-fold selectivity versus related LOX isozymes, was a mixed inhibitor, and did not reduce the active-site ferric ion. Lastly, 1 significantly reduced infarct size following permanent focal ischemia in a mouse model of ischemic stroke. As such, this represents the first report of a selective inhibitor of human 12/15-LOX with demonstrated in vivo activity in proof-of-concept mouse models of stroke.

31 January 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VKVictor Kenyon
Victor Kenyon
ICIlya Chorny
Ilya Chorny
WCWendy J. Carvajal
Wendy J. Carvajal
THTheodore R. Holman
Theodore R. Holman
MJMatthew P. Jacobson
Matthew P. Jacobson

24 September 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GRGanesha Rai
Ganesha Rai
VKVictor Kenyon
Victor Kenyon
AJAjit Jadhav
Ajit Jadhav
LSLena Schultz
Lena Schultz
MAMichelle Armstrong
Michelle Armstrong
DMDavid J. Maloney
David J. Maloney

25 October 2007 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
Klaus Van LeyenKlaus Van Leyen
Klaus Van Leyen
KAKen Arai
Ken Arai
GJGuang Jin
Guang Jin
VKVictor Kenyon
Victor Kenyon
BGBettina Gerstner
Bettina Gerstner
ELEng H. Lo
Eng H. Lo